The U.S. FDA has granted Orphan Drug designation for DiaPep277 for the treatment of type 1 diabetes (T1D) patients with residual beta cell function. The designation of Orphan Drug status offers 7 years marketing exclusivity from the time of approval…. Read more
Diapep277 was discovered in 1990 by Professor Irun Cohen and his team at the Weizmann Institute’s Department of Immunology… Read more
Andromeda Biotech has announced positive initial results from a pivotal phase III clinical study of type 1 diabetes treatment, DiaPep227.
The 24-month randomized, placebo-controlled study was designed to assess the safety and efficacy of DiaPep277, a novel immunotherapeutic agent for the treatment of newly diagnosed patients with type 1 diabetes… Read more
When I was first diagnosed with type 1 diabetes, I was asked to participate in a clinical study for a diabetes “vaccine” called Diapep277. I didn’t know anything about it (nor did I know anything about diabetes). At the time, … Read more